Clinical Trials List
2024-03-01 - 2028-10-10
Phase II
Not yet recruiting4
Recruiting1
ICD-10C45.9
Mesothelioma, unspecified
ICD-10C79.9
Secondary malignant neoplasm of unspecified site
ICD-10C7A.00
Malignant carcinoid tumor of unspecified site
ICD-10C7A.094
Malignant carcinoid tumor of the foregut NOS
ICD-10C7A.095
Malignant carcinoid tumor of the midgut NOS
ICD-10C7A.096
Malignant carcinoid tumor of the hindgut NOS
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.00
Secondary carcinoid tumors, unspecified site
ICD-10C80.1
Malignant (primary) neoplasm, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.1
Malignant neoplasm of unspecified site (primary) (secondary)
-
Trial Applicant
Daiichi Sankyo Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Wen-Chi Chou Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- 陳宏吉 Division of Ophthalmology
- Cheng-Lung Hsu Division of Hematology & Oncology
- Chan-Keng Yang Division of Hematology & Oncology
- 陳建銘 Division of Radiology
- 吳教恩 Division of Hematology & Oncology
- Wen-Cheng Chang Division of Hematology & Oncology
- Hung-Ming Wang Division of Hematology & Oncology
- Hung-Chih Hsu Division of Hematology & Oncology
- Chi-Ting Liau Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 李易濰 Division of Radiology
- 陳彥豪 Division of Hematology & Oncology
- 林昶廷 Division of Hematology & Oncology
- 黃詩喻 Division of Hematology & Oncology
- 陳怡豪 Division of Ophthalmology
- Shau-Hsuan Li Division of Hematology & Oncology
- 郭明濬 Division of Hematology & Oncology
- Yu-Li Su Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- 劉建廷 Division of Hematology & Oncology
- 姜威宇 Division of Ophthalmology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Jih-Hsiang Lee Division of Hematology & Oncology
- HUAI-CHENG HUANG Division of Hematology & Oncology
- 徐偉勛 Division of Hematology & Oncology
- Kun-Huei Yeh Division of Hematology & Oncology
- 吳宗哲 Division of Hematology & Oncology
- 陳國興 Division of Hematology & Oncology
- Hsin-Yu Liu Division of Ophthalmology
- 梁逸歆 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 姜乃榕 Division of Hematology & Oncology
- Ming-Huang Chen Division of Hematology & Oncology
- Chun-Yu Liu Division of Hematology & Oncology
- Yi-Ping Hung Division of Hematology & Oncology
- Tien-Hua Chen Division of Hematology & Oncology
- 林泰祺 Division of Ophthalmology
- Mu-Hsin Chang Division of Hematology & Oncology
- 周昱百 Division of Ophthalmology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 顏志傑 Division of Hematology & Oncology
- Wei-Pang Chung Division of Hematology & Oncology
- Shang-Yin Wu Division of Hematology & Oncology
- 劉奕廷 Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
- Yu-Min Yeh Division of Hematology & Oncology
- Yuh-Shyan Tsai Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
640 participants
